Bisphosphonates in the Adjuvant Setting of Breast Cancer Therapy—Effect on Survival: A Systematic Review and Meta-Analysis

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial

(2012) Alexander HG Paterson et al.   LANCET ONCOLOGY

Breast-Cancer Adjuvant Therapy with Zoledronic Acid

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer

(2011) R. Coleman et al.   BREAST CANCER RESEARCH AND TREATMENT

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial

(2011) Michael Gnant et al.   LANCET ONCOLOGY

Breast-Cancer Adjuvant Therapy with Zoledronic Acid

(2011) Robert E. Coleman et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Protective Effect of Zoledronic Acid on Bone Loss in Postmenopausal Women with Early Breast Cancer Treated with Sequential Tamoxifen and Letrozole: A Prospective, Randomized, Phase II Trial

(2011) Tamar Safra et al.   ONCOLOGY

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study

(2010) H. Eidtmann et al.   ANNALS OF ONCOLOGY

Randomized Trial of Adjuvant Zoledronic Acid in Postmenopausal Women With High-Risk Breast Cancer

(2010) Ticiana Leal et al.   Clinical Breast Cancer

Bisphosphonates as Treatment of Bone Metastases

(2010) Ingunn Holen et al.   CURRENT PHARMACEUTICAL DESIGN

Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease

(2010) H.L. Neville-Webbe et al.   EUROPEAN JOURNAL OF CANCER

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial

(2010) Catherine Van Poznak et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women

(2010) Rowan T. Chlebowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Bisphosphonates and Risk of Postmenopausal Breast Cancer

(2010) Gad Rennert et al.   JOURNAL OF CLINICAL ONCOLOGY

Potential Anticancer Properties of Bisphosphonates

(2010) Helen L. Neville-Webbe et al.   SEMINARS IN ONCOLOGY

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy

(2009) P. Hadji et al.   ANNALS OF ONCOLOGY

Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis

(2009) Davide Mauri et al.   BREAST CANCER RESEARCH AND TREATMENT

Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results

(2009) Adam M. Brufsky et al.   Clinical Breast Cancer

Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone

(2009) P. D. Ottewell et al.   MOLECULAR CANCER THERAPEUTICS

Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer

(2008) Bent Kristensen et al.   ACTA ONCOLOGICA

Practical guidance for the management of aromatase inhibitor-associated bone loss

(2008) P. Hadji et al.   ANNALS OF ONCOLOGY

Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow--a long-term follow-up

(2008) I. J. Diel et al.   ANNALS OF ONCOLOGY

Exploring the anti-tumour activity of bisphosphonates in early breast cancer

(2008) M.C. Winter et al.   CANCER TREATMENT REVIEWS

Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer

(2008) J. E. Lester et al.   CLINICAL CANCER RESEARCH

Oral nitrogen-containing bisphosphonates: a systematic review of randomized clinical trials and vertebral fractures

(2008) Gerolamo Bianchi et al.   CURRENT MEDICAL RESEARCH AND OPINION

Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

(2008) Susan L. Greenspan et al.   JOURNAL OF CLINICAL ONCOLOGY